Home › Funds › Saturn V Capital Management LP › TRVI
Saturn V Capital Management LP position in TRVI
TREVI THERAPEUTICS INC · Health Care
Saturn V Capital Management LP reported holding 1,573,876 shares of TRVI (TREVI THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$22.5M, representing 3.30% of its reported portfolio and ranking #12 among its reported holdings. Saturn V Capital Management LP has disclosed TRVI holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Saturn V Capital Management LP's TRVI position evolved
Saturn V Capital Management LP first disclosed a stake in TRVI in Q2 2026 at 1,052,043 shares (US$19.6M). The position peaked in Q3 2026 at 1,573,876 shares, worth US$22.5M. Across 2 filings, Saturn V Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,573,876 shares valued at US$22.5M — an increase of 521,833 shares quarter over quarter.. Notable position changes include a 50% increase in Q3 2026 (shares fell 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 1.05M | $19.62M | New |
| Q3 2026 | 1.57M | $22.54M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRVI and 13F data
TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 58 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$60.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRVI
- NEA Management Company, LLC 13.22M sh · $246.59M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.94M sh · $185.37M · Q2 2026
- Vivo Capital, LLC 4.23M sh · $60.57M · Q3 2026
- Vestal Point Capital, LP 3.10M sh · $57.81M · Q2 2026
- MPM BioImpact LLC 3.07M sh · $57.32M · Q2 2026
- First Light Asset Management, LLC 2.10M sh · $39.11M · Q2 2026
- Artia Global Partners LP 2.21M sh · $31.66M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 2.14M sh · $30.71M · Q3 2026
- ORBIMED ADVISORS LLC 1.43M sh · $26.67M · Q2 2026
- Affinity Asset Advisors, LLC 1.80M sh · $25.78M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.74M sh · $24.96M · Q3 2026
- Soleus Capital Management, L.P. 1.18M sh · $22.00M · Q2 2026
More on Saturn V Capital Management LP
FAQ
How long has Saturn V Capital Management LP held TRVI?
Saturn V Capital Management LP has disclosed TRVI holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Saturn V Capital Management LP's current position in TRVI?
As of Q3 2026, Saturn V Capital Management LP holds 1.57M shares of TRVI (TREVI THERAPEUTICS INC), valued at $22.54M, representing 3.30% of its reported portfolio and ranking #12.
Has Saturn V Capital Management LP been buying or selling TRVI?
In the latest 13F filing (Q3 2026), Saturn V Capital Management LP increased its position in TRVI. The position peaked in Q3 2026 at 1.57M shares.
Which other funds hold TRVI?
Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 58 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.